Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tilarginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 known ✓ | P35228 | 5/20 | 0.46 |
| ▸ | NOS3 known ✓ | P29474 | 4/20 | 0.46 |
| ▸ | NOS1 known ✓ | P29475 | 4/20 | 0.46 |
| ▸ | OTC | P00480 | 1/20 | 0.51 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 4/20 | 0.41 |
| ▸ | ARG1 | P05089 | 3/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tilarginine SCHEMBL12028766 | 1.00 | OTC (0.51) | OTCNOS2NOS3NOS1DDAH1 | |
| Tilarginine SCHEMBL6370536 | 1.00 | OTC (0.51) | OTCNOS2NOS3NOS1DDAH1 | |
| Tilarginine SCHEMBL2229626 | 0.98 | OTC (0.50) | OTCNOS2NOS3NOS1DDAH1 | |
| Tilarginine SCHEMBL1321022 | 0.97 | OTC (0.49) | OTCNOS2NOS3NOS1DDAH1 | |
| SCHEMBL1006081 | 0.95 | GSR (0.47) | OTCNOS2NOS3NOS1DDAH1 | |
| SCHEMBL14423587 | 0.95 | GSR (0.47) | OTCNOS2NOS3NOS1DDAH1 | |
| SCHEMBL4393876 | 0.89 | PMP22 (0.43) | OTCNOS2NOS3NOS1GSR | |
| SCHEMBL29533865 | 0.89 | PMP22 (0.43) | OTCNOS2NOS3NOS1GSR | |
| SCHEMBL19608041 | 0.86 | DPP7 (0.41) | OTCNOS2NOS3NOS1DDAH1 | |
| SCHEMBL12279136 | 0.86 | DPP7 (0.41) | OTCNOS2NOS3NOS1DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1857 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745237-A1 | RNAI AGENT FOR INHIBITING EXPRESSION OF KETOHEXOKINASE AND USE THEREOF | YUN HO BIO CO., LTD (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2026100273-A1 | METHOD FOR PRODUCING USEFUL SUBSTANCE, CULTURE SOLUTION FOR CULTURING ALGAE, APPARATUS FOR PRODUCING USEFUL SUBSTANCE, AND ALGAE CONTAINING USEFUL SUBSTANCE | ＮＴＴ株式会社 | 2026-05-15 | — | — | WO | claimed |
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | claimed |
| US-20260102400-A1 | PHARMACEUTICAL COMPOSITION FOR DISRUPTING TUMOR BLOOD VESSELS | SAMSUNG MEDICAL FOUND (KR) | 2026-04-16 | — | — | US | claimed |
| EP-3338813-B2 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2026-04-15 | — | — | EP | claimed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-3558399-B2 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2026-01-14 | — | — | EP | claimed |
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | claimed |
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | claimed |
| CN-1203893-C | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2005-06-01 | — | — | CN | claimed |
| WO-2005041886-A2 | METHODS FOR GENERATING OR INCREASING REVENUES RELATED TO PAIN INHIBITOR COMMERCE | METAPHORE PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| WO-2005041894-A2 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, REVERSING AND INHIBITING PAIN | METAPHORE PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-20040072809-A1 | Antiinflammatory agents; analgesics; dilation; reducing pressure; therapy for vision defects | OMEROS CORPORATION | 2004-04-15 | — | — | US | claimed |
| WO-2003084528-A1 | A METHOD FOR REVERSING PERMEABILITY MODIFICATIONS CAUSED BY ACUTE PERITONITIS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2003-10-16 | — | — | WO | claimed |
| US-6471997-B1 | ANTAGONIST OF CALCITONIN GENE RELATED PEPTIDE, CGRP AND/OR OF SUBSTANCE P; COSMETIC | SOCIETE L'OREAL S.A. (FR) | 2002-10-29 | — | — | US | claimed |
| US-20020156129-A1 | Method of treating pruritus and a pharmaceutical composition for the method | IKEDA MOHANDO CO., LTD. (JP) | 2002-10-24 | — | — | US | claimed |
| WO-2002069910-A2 | USE OF SUBSTANCES THAT PREVENT THAT THE NO SYNTHASE OF WARM-BLOODED ORGANISMS TAKES EFFECT, FOR PRODUCING COSMETIC OR DERMATOLOGICAL PREPARATIONS FOR THE TREATMENT AND/OR THE PROPHYLAXIS OF UNDESIRED SKIN PIGMENTATION | BEIERSDORF AG (DE) | 2002-09-12 | — | — | WO | claimed |
| CN-1326785-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2001-12-19 | — | — | CN | claimed |
| EP-0765668-A1 | Extract of Iridaceas and composition containing it | L'OREAL (FR) | 1997-04-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | NOS2 4412/4885NOS3 4331/4885NOS1 4480/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | NOS2 3704/4885NOS3 2987/4885NOS1 3927/4885 |
| US-20260102400-A1 | PHARMACEUTICAL COMPOSITION FOR DISRUPTING TUMOR BLOOD VESSELS | RNMT, PNP, NOS1 | NOS2 26/4885NOS3 4/4885NOS1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.